Navigation Links
Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol
Date:8/17/2011

CHADDS FORD, Pa., Aug. 17, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it is terminating its research program and collaboration related to the development of axomadol. Endo licensed exclusive rights to develop and market axomadol in the United States and Canada from Grunenthal in February 2009.

"As a leader in the field of pain management, Endo remains committed to the development and commercialization of pain therapeutics," said Ivan Gergel, M.D., executive vice president, R&D, Endo Pharmaceuticals. "We have appreciated the opportunity to collaborate with Grunenthal on this program and they have been an excellent partner."

The company recently announced topline results from a phase 2 study comparing the novel investigational drug axomadol against placebo in the treatment of patients with moderate to severe chronic low back pain. The results indicate that axomadol did not meet predetermined study end points.

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments – branded pharmaceuticals, generics and devices and services.  We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit http://www.endo.com/.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Statements including words such as "believes," "expects," "anticipates," "intends,"
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... subsidiary, BreedIT Ltd., the exclusive worldwide distributor of highly ... announced that on January 7, 2014, the Company,s board ... Ben-Zion Weiner as its new member of ... Weiner held executive positions with Teva Pharmaceutical Industries Ltd ...
(Date:1/15/2014)... -- MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ... than 10 bps, yet are surprisingly capable in their ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 /PRNewswire/ ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ... the market as insulin delivery systems especially ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... ... is spearheading an online grass roots movement to protect the Dietary Supplement Health and Education ... health alternatives. , ... CA (PRWEB) June 29, 2009 -- The Natural Health Freedom Movement , a new ...
... ... a man with paralysis who has traveled to India for stem cell treatment that he ... ... Wheels, is a paraplegic who has received stem cell treatments in India. His progress is ...
... / ST. PAUL (June 24, 2009) University of ... colleagues found that one in seven adolescents believe that ... age 35, and this belief predicted that the adolescents, ... analyzed data collected by the National Longitudinal Study of ...
... the UK have backed a call by the Wellcome ... records can be safely used in research. Patient ... of information which can help medical researchers improve their ... patient care. The increasing use of electronic records should ...
... Hemorrhoids, incontinence and more can result, research shows , ... health problem, it turns out, is associated with potentially ... review of the scientific evidence, researchers found that constipation ... serious complications such as hemorrhoids, anal fissures, fecal incontinence, ...
... ... Jackson International is providing interactive online resources for medical travelers (medical tourists) and ... their affiliate physician HIPAA compliant access to medical records and information to better provide ... ...
Cached Medicine News:Health News:Americans' Right to Access Natural Health Alternatives in Peril, Says Natural Health Freedom Movement 2Health News:Americans' Right to Access Natural Health Alternatives in Peril, Says Natural Health Freedom Movement 3Health News:Americans' Right to Access Natural Health Alternatives in Peril, Says Natural Health Freedom Movement 4Health News:Americans' Right to Access Natural Health Alternatives in Peril, Says Natural Health Freedom Movement 5Health News:Paraplegic Takes Leap of Faith for Treatment in India 2Health News:Teens who believe they'll die young are more likely to engage in risky behavior, University of Minnesota research finds 2Health News:GP bodies support guidelines for use of patient records in medical research 2Health News:Constipation May Lead to Other Problems 2Health News:Constipation May Lead to Other Problems 3Health News:Jackson International Launches New Website in Collaboration with Medicaview International 2Health News:Jackson International Launches New Website in Collaboration with Medicaview International 3Health News:Jackson International Launches New Website in Collaboration with Medicaview International 4
... Medtronic has been a key participant ... for more than a decade. Previous Medtronic ... for concentrated platelets, as well as to ... for producing platelet-rich plasma (PRP) for a ...
This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
... Biliary Self-Expanding Stent System combines low-profile, high radial ... .018" guide wire compatible stent system provides 6F ... diameters (5.0 - 10.0 mm). Now, with longer ... in five stent lengths (28, 38, 56, 80 ...
... Supreme and Response catheters comprise ... catheters available for electrophysiology procedures. Their ... provide for superior torque response with ... multiple curves and French sizes, Supreme ...
Medicine Products: